Value of juvenile animal studies

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 92, Issue 4, 2011, Pages 292-303

  Leconte, Isabelle ^a,l   Bailey, Graham ^b   Davis Bruno, Karen ^c   Hew, Kok Wah ^d   Kim, James ^e   Silva Lima, Beatriz ^f   Liminga, Ulla ^g   Moffit, Jeffrey ^h   De Schaepdrijver, Luc ^b   Schmitt, Georg ⁱ   Tassinari, Melissa ^c   Thompson, Kary ^j   Hurtt, Mark ^k  

^a SANOFI   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

^e ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^f RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^g MEDICAL PRODUCTS AGENCY   (Sweden)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j BRISTOL MYERS SQUIBB   (United States)

^k PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^l NONE   (France)

more..

Author keywords

Pharmaceuticals; Postnatal evaluation; Safety assessment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE INHIBITOR; MONOCLONAL ANTIBODY; MU OPIATE RECEPTOR AGONIST; MUSCLE RELAXANT AGENT; SODIUM CHANNEL BLOCKING AGENT; VALPROIC ACID;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALOPECIA; ANEMIA; ANIMAL EXPERIMENT; CANCER PAIN; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFECTION; LIVER DISEASE; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERACTIVE BLADDER; PEDIATRICS; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; VOMITING; XEROSTOMIA;

ANIMALS; ANIMALS, LABORATORY; DRUG EVALUATION, PRECLINICAL; MODELS, ANIMAL; RISK ASSESSMENT; TOXICITY TESTS;

ANIMALIA;

EID: 80051934019     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20331     Document Type: Review

References (18)

1. Bailey GP, Marien D. 2011. The value of juvenile animal studies, "What have we learned from pre-clinical juvenile toxicity studies? II" Birth Defects Res B Dev Reprod Toxicol 92:273-291.
2. Beck MJ, Padgett EL, Bowman CJ, et al. 2006. Nonclinical juvenile toxicity testing. In: Hood RD, editor. Developmental and reproductive toxicology. Boca Raton: CRC Press. p 263-267.
3. Bowman C, Chmielewski G, Lewis E, et al. 2011. Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges. Birth Defects Res B Dev Reprod Toxicol 92:333-344.
4. Buse E. 2005. Development of the immune system in the cynomolgus monkey: the appropriate model in human targeted toxicology? J Immunotoxicol 2:211-216.
5. 2 nicotinic acetylcholine receptor partial agonist CP-601, 927. Birth Defects Res B Dev Reprod Toxicol 92:323-332.
6. Cappon GD. 2011. Nonclinical support of pediatric drug development in a global context: an industry perspective. Birth Defects Res B Dev Reprod Toxicol 92:269-272.
7. Cappon GD, Bailey GP, Buschmann J, et al. 2009. Juvenile animal toxicity study designs to support pediatric drug development. Birth Defects Res B Dev Reprod Toxicol 86:463-469.
8. Cappon GD, Chapin RE, Hurtt ME, et al. 2011. Impaired reproduction in adult male, but not female, rats following juvenile treatment with the armoatase inhibitor, Exemestane. Birth Defects Res B Dev Reprod Toxicol (in press).
9. Carleer J, Karres J. 2011. Juvenile animal studies and pediatric drug development: a European perspective. Birth Defects Res B Dev Reprod Toxicol 92:254-260.
10. EMEA. 2008. European Medicines Agency (EMEA), Committee for Human medicinal Products (CHMP). Guideline on the need for nonclinical testing in juvenile animals on human pharmaceuticals for paediatric indications. Available at.
11. FDA. 2006. United States Food and Drug Administration (FDA). Guidance document. Nonclinical safety evaluation of pediatric drug products. Available at.
12. Holsapple MP, West LJ, Landreth KS. 2003. Species comparison of anatomical and functional immune system development. Birth Defects Res B Dev Reprod Toxicol 68:321-334.
13. Hurtt ME, Daston G, Davis-Bruno K, et al. 2004. Juvenile animal studies: testing strategies and design. Birth Defects Res B Dev Reprod Toxicol 71:281-288.
14. ICH Harmonized Tripartite Guideline. 2009. Guidance on the Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3 (R2).
15. Silva-Lima B, Theilade-Thomsen MD, Carleer J, et al. 2010. Juvenile animal studies for the development of paediatric medicines: A description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors. Birth Defects Res B Dev Reprod Toxicol 89:467-473.
16. Tassinari MS, Benson K, Elayan I, et al. 2011. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling. Birth Defects Res B Dev Reprod Toxicol (in press).
17. Thorsrud BA, Faqi AS, Holdsworth DL, Baird TJ. 2010. Comparative analysis of cardiac rhythum and quantitative elements of the electrocardiogram in juvenile and adult beagle dogs. Toxicologist 114:450.
18. Wise LD, Stoffregen DA, Hoe CM, Lankas GR. 2011. Juvenile toxicity assessment of open-acid lovastatin in rats. Birth Defects Res B Dev Reprod Toxicol 92:314-322.